{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"SDX-7320"},{"type":"Synonym","name":"methionine aminopeptidase type II inhibitor SDX-7320"},{"type":"CASRegistryName","name":"2416263-67-5"},{"type":"Synonym","name":"MetAP2 inhibitor SDX-7320"}],"definition":{"html":"A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.","text":"A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates."},"drugInfoSummaryLink":null,"nciConceptId":"C128030","nciConceptName":"Evexomostat","termId":781275,"name":"evexomostat","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"evexomostat"}],"links":null}